Evidence map›Paper›PMID 39296315›Full record

ArticleJournal of psoriasis and psoriatic arthritis2023

Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities.

Andrew Blauvelt, George C Gondo, Stacie Bell, Cristina Echeverría, Marcus Schmitt-Egenolf, Lone Skov, Peter van de Kerkhof, Leah McCormick Howard, Bruce Strober

Abstract read
In one paragraph

Article in Journal of psoriasis and psoriatic arthritis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrew BlauveltOregon Medical Research Center, Portland, OR, USA.
George C GondoNational Psoriasis Foundation, Portland, OR, USA.ORCID https://orcid.org/0000-0002-6468-0397
Stacie BellNational Psoriasis Foundation, Portland, OR, USA.ORCID https://orcid.org/0000-0002-9987-567X
Cristina EcheverríaInstituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina.
Marcus Schmitt-EgenolfDepartment of Public Health & Clinical Medicine, Umeå University, Umea, Sweden.
Lone SkovDepartment of Dermatology and Allergy, University of Copenhagen, Copenhagen, Denmark.
Peter van de KerkhofNijmegen Medical Centre, Radboud University, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0003-0084-3131
Leah McCormick HowardNational Psoriasis Foundation, Portland, OR, USA.
Bruce StroberYale University School of Medicine, New Haven, CT, USA.ORCID https://orcid.org/0000-0002-8394-2057

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Psoriasis severity has traditionally been categorized as mild, moderate, and severe. Commonly, cut-offs for severe disease require a body surface area (BSA) involvement of ≥10% or a Psoriasis Area Severity Index (PASI) > 10. However, clinical experience challenges these traditional measures and requirements, as patients with less extensive psoriasis may have disease that severely impacts quality of life. Objective: The objective of the present study was to further explore the extent of patient burden when psoriasis affects special locations. Methods: A total of 69,190 individuals living in the U.S were invited to participate in a patient advocacy survey by telephone and or web interviews over the course of 3 years (2019-2021). The survey instrument consisted of validated patient-reported outcome measures, measuring disease-specific quality of life (Dermatology Life Quality Index, DLQI), depression (Patient Health Questionnaire (PHQ)-2 and (PHQ)-9), and the ability to participate in social roles and activities (PROMIS Ability to Participate in Social Roles and Activities (SF-4a). Chi-square tests were performed to explore association between psoriasis involvement on special locations and patient outcomes and multivariate logistic regression models were then constructed, to assess impact of having psoriasis on special locations patient outcomes, controlling for potential confounding factors. Results: A total of 4129 individuals completed the survey. 3594 (84.4%) of patients surveyed reported psoriasis involving special areas of the bodysuch as the scalp, face, hands, feet, or genitalia. Involvement of special areas is associated with worse quality of life and depression. 35-71% of patients with 10% or less total BSA involvement experienced a moderate-to-extremely large effect on these life function domains. When adjusting for age, sex, and body surface area, psoriasis involvement of a special location was associated with poorer patient reported outcomes, including a 46% less likelihood of reporting their skin disease as having "no or only a small effect on QoL," a 30% less likelihood of having a "normal l ability to participate in social roles and activities," and a 126% higher likelihood of f having depression. Conclusion: Real-world data presented here demonstrate that psoriasis involving special areas is associated with adverse life consequences, including poor quality of life and depression.

Indexed as

disease severitymental healthpsoriasisquality of lifetreatment

Identifiers

PMID39296315
PMCPMC11361513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.